CurrentCignaPolicy IP0259

Drug Coverage Policy (Oral - Sphingosine 1-Phosphate Receptor Modulator) Fingolimod

Cigna drug coverage policy for fingolimod (Gilenya and generic fingolimod capsules) for treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS in patients aged 6gt;=10 years. Part 1 provides overview, indications, disease and safety background, and administrative instructions; clinical coverage criteria and coding likely appear in subsequent parts.

Policy Summary

PayerCigna

PolicyDrug Coverage Policy (Oral - Sphingosine 1-Phosphate Receptor Modulator) Fingolimod

Policy CodePolicy IP0259

Change TypeRevision / Additions

Effective DateNov 1, 2025

Next Review Date

Key ActionDocument diagnosis of relapsing forms of MS and patient age (≥10 years) when seeking coverage or reimbursement.

SourceLink

POLICY UPDATE CHANGES

Added a definition for documentation.

Added a requirement for a patient to be 6gt;= 10 years of age.

Added a specialist prescribing requirement.

Added criteria for patient Currently Receiving Fingolimod for 6gt;= 1 Year.

Updated the preferred product multi-source brand language to current standards.

Ocrevus Zunovo was added to the Appendix.

Policy name changed to add 'Oral - Sphingosine 1-Phosphate Receptor Modulator' and a policy statement was added in an earlier revision; documentation requirements were removed and Employer/Individual plan preferred product criteria updated.

>=10Minimum Age for Indication

6hFirst-dose observation time

Yes

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Covered indication (MS)

1 yrApproval duration (per approval)

Concurrent/non-relapsingNot-covered uses

Coverage Summary & FDA-Approved Indication

Cigna covers fingolimod (Gilenya® and generic fingolimod capsules) for the treatment of relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing‑remitting MS, and active secondary progressive MS) in patients aged ≥10 years. Coverage is mixed/plan‑specific with preferred‑product rules that differ by line of business (Employer and Individual/Family plans) and require trials of the bioequivalent generic fingolimod capsule unless a documented inability to tolerate an inactive ingredient exists. Prior authorization and specialist prescribing requirements apply.

Indications / Overview

Fingolimod is indicated when ALL of the following are met:

ALL of the following

Diagnosis of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease
Patient is ≥ 10 years of age>= 10 years

FDA-Approved Indication - Multiple Sclerosis

Approve for the duration noted below if the patient meets one of the following (A or B):

A) Initial Therapy
- Patient has a relapsing form of multiple sclerosis
- Patient is ≥ 10 years of age>= 10 years
- Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis
- Preferred product criteria is met for the product(s) as listed in the below table(s)
  Employer/Individual plan variants require trial of generic fingolimod capsules unless contraindicated by inactive ingredient
B) Patient is Currently Receiving Fingolimod for ≥ 1 Year

Safety, First-Dose Monitoring & Required Provider Actions

Safety / First-dose monitoring

{

"operator":"all","children":[

{"text":"Administer the first dose in a clinical setting with resources to manage symptomatic bradycardia (e.g., personnel trained in ACLS, resuscitation equipment, and access to ECG/monitoring).","note":"First-dose environment requirement."},

{"text":"Observe patients for signs and symptoms of bradycardia for a minimum of 6 hours after the first fingolimod dose.","threshold":"6 hours"},

{"text":"If baseline QTc is prolonged or QTc prolongation or other cardiac conduction abnormalities occur during the observation period, or the patient is taking medications known to increase risk of torsades de pointes, admit for overnight continuous ECG monitoring.","note":"Overnight ECG indicated for QTc concerns or interacting medications."},

Referenced Products & Codes

Drug product mentionsmixed

Gilenya	Brand name fingolimod capsules (Novartis) — listed as Gilenya®
fingolimod capsules - generic	Generic fingolimod capsules

Referenced products / appendixmixed

Gilenya 0.5 mg (fingolimod 0.5 mg capsule)	branded product referenced; oral
Tascenso ODT (fingolimod orally disintegrating tablets)	fingolimod orally disintegrating tablets referenced
Other disease-modifying therapies (examples listed in Appendix)	Aubagio, Avonex, Bafiertam, Betaseron, Briumvi, Copaxone, Glatopa, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ocrevus Zunovo, Plegridy, Ponvory, Rebif, Tecfidera, Tyruko, Tysabri, Vumerity, Zeposia (ozanimod)

Evidence & Key Trials

Key evidence sources include the Gilenya prescribing information (Novartis; June 2024) and pivotal trials such as the INFORMS study (Lancet 2016) which found that fingolimod did not slow disease progression in primary progressive MS. Safety concerns noted in the evidence and label include transient decreases in heart rate after the first dose (with recommended 6‑hour observation), atrioventricular conduction abnormalities, increased infection risk, macular edema, pulmonary toxicity, elevated liver enzymes, and rare postmarketing cases of progressive multifocal leukoencephalopathy (PML).

Background & Definitions

Fingolimod is a sphingosine 1‑phosphate receptor modulator indicated for patients with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease, in patients aged ≥10 years. Multiple sclerosis is a chronic inflammatory demyelinating autoimmune disease of the central nervous system with relapsing and progressive courses; approximately 85%–90% of patients present with a relapsing pattern. Disability in MS is commonly measured with the Expanded Disability Status Scale (EDSS), an ordinal scale from 0 to 10 with higher scores indicating greater disability.

Clinically isolated syndrome — First clinical presentation of inflammatory demyelination that may be MS but has not yet fulfilled diagnostic criteria.

EDSS — Expanded Disability Status Scale, an ordinal scale from 0 to 10 grading disability in MS (higher scores indicate greater disability).

Relapsing form of multiple sclerosis — Includes clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease.

Policy Changes & Revision Timeline

12/01/2024added (material)

Added a requirement that patient be ≥ 10 years of age (material).

12/01/2024added (material)

Added a specialist prescribing requirement — fingolimod must be prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis (material).

12/01/2024added (material)

Added criteria for patients currently receiving fingolimod for ≥ 1 year, including requirement for documented beneficial clinical response on at least one objective measure or stabilization/improvement in at least one symptom (material).

Policy Summary

PayerCigna

PolicyDrug Coverage Policy (Oral - Sphingosine 1-Phosphate Receptor Modulator) Fingolimod

Policy CodePolicy IP0259

Change TypeRevision / Additions

Effective DateNov 1, 2025

Next Review Date

Key ActionDocument diagnosis of relapsing forms of MS and patient age (≥10 years) when seeking coverage or reimbursement.

SourceLink

On This Page

Patient has a relapsing form of multiple sclerosis

Patient is ≥ 10 years of age>= 10 years

Clinical response

Patient experienced a beneficial clinical response when assessed by at least one objective measure (examples: stabilization or reduced worsening on MRI [absence/decrease in gadolinium enhancing lesions or fewer new/enlarging T2 lesions]; stabilization/reduced worsening on EDSS; achievement of NEDA-3 or NEDA-4; improvement on FSIQ-RMS; reduction/absence of relapses; improvement/maintenance on 6-minute walk or 12-Item MS Walking Scale; improvement on MSFC; attenuation of brain volume loss)
Patient experienced stabilization, slowed progression, or improvement in at least one symptom (examples: motor function, fatigue, vision, bowel/bladder function, spasticity, walking/gait, pain/numbness/tingling)

Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis

{"text":"If fingolimod is restarted after a gap of >14 days following the first treatment month, repeat first-dose monitoring and observation as above.","threshold":">14 days","note":"Restart monitoring requirement."},

Do not initiate fingolimod in patients with contraindicating cardiovascular conditions (e.g., recent myocardial infarction, unstable angina, stroke, decompensated heart failure, certain conduction abnormalities) unless benefits clearly outweigh risks and appropriate cardiology consult/documentation is provided.

Cardiovascular contraindication considerations.

Prior Authorization

Prior Authorization Required

Prior authorization is required for fingolimod; approvals are typically issued for 1 year when criteria are met.

Prior authorization is required
Approval duration: 1 year

Documentation Required

First-dose administration & monitoring

Administer the first fingolimod dose in a setting equipped to manage symptomatic bradycardia and observe the patient for at least 6 hours; obtain baseline and post-dose ECG as indicated and perform overnight continuous ECG monitoring if prolonged QTc or interacting QT-prolonging medications are present.

First-dose observation: 6 hours
Restart first-dose monitoring when restarted >14 days after the first treatment month

Documentation Required

Documentation & Prescriber Requirements

Document the diagnosis of relapsing forms of multiple sclerosis and patient age (≥ 10 years). Medication should be prescribed by, or in consultation with, a neurologist or MS specialist. For continuation/renewal, document clinical response and that appropriate first-dose/restart monitoring was completed when applicable.

Diagnosis documentation: relapsing forms of MS
Patient age documented: ≥ 10 years
Prescriber: neurologist or MS specialist, or documented consultation
Clinical response documentation required for continuation
Documentation of first-dose/restart monitoring when applicable

Denial Risk

Not medically necessary / Denial risk

Concurrent use with other disease-modifying therapies and use for non-relapsing forms of MS (e.g., primary progressive MS) are considered not medically necessary and may lead to denial.

Concurrent use with other DMTs is not medically necessary
Use for non-relapsing MS (e.g., primary progressive MS) is not medically necessary

Billing Rule

Plan-specific preferred product & approval duration

Some employer/individual plan variants require trial of generic fingolimod prior to approval for branded product; approvals are generally for 1 year. Check plan-specific requirements for preferred product and step edits.

Plan variants may require trial of generic fingolimod before branded approval
Approval duration: 1 year

12/01/2024added

Added a definition for documentation (administrative).

12/01/2024updated

Updated the preferred product multi-source brand language to current standards (administrative).

12/01/2024added

Ocrevus Zunovo was added to the Appendix (administrative).

11/01/2025revised (administrative)Latest

Early Annual Revision dated 11/01/2025: Policy name changed to add 'Oral - Sphingosine 1-Phosphate Receptor Modulator'; a policy statement was added in an earlier revision; documentation requirements were removed and Employer/Individual plan preferred product criteria updated (administrative).